Complement, Coagulation & FcRn

Cat. No.

AT0722

CAS No.

1803171-55-2

Ravulizumab

Synonyms: ALXN1210

Ravulizumab (ALXN1210) is a humanized monoclonal antibody engineered to bind with high affinity to the human complement protein C5. This antibody is pivotal in the inhibition of the terminal complement cascade, a key component in immune response and inflammation. Ravulizumab is primarily utilized in the investigation of diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis, offering a significant tool for understanding the pathophysiology and therapeutic interventions of these conditions.

Cat. No.

AT0756

CAS No.

2101829-58-5

ACT017

ACT017 is a humanized Fab fragment of an anti-GPVI monoclonal antibody designed to inhibit collagen-induced platelet aggregation. This product is specifically developed for research applications focusing on acute ischemic stroke, providing a valuable tool for studies aimed at understanding and potentially intervening in platelet aggregation pathways during ischemic events.

Cat. No.

AT0758

CAS No.

2955620-21-8

Zemocimig

Zemocimig is a human IgG4 κ monoclonal antibody targeting coagulation factor F9. For optimal experimental control, it is recommended to use Human IgG4 kappa Isotype Control.

Cat. No.

AT0798

Anti-Complement C5aR1 Antibody

Cat. No.

AT0799

CAS No.

2210314-30-8

Olendalizumab

Synonyms: ALXN1007

Olendalizumab (ALXN1007) is a humanized monoclonal antibody derived from mouse IgG2-G4-κ, specifically designed to target Complement protein C5a with a dissociation constant (Ki) of 60 pM. This antibody plays a crucial role in modulating the complement inflammatory pathway. Olendalizumab is primarily utilized in research focused on complement-mediated disorders, particularly those associated with coronavirus infections. This specificity and application make it a valuable tool for studies aimed at understanding and potentially mitigating the impact of complement system dysregulation in viral diseases.

Cat. No.

AT0808

CAS No.

2842046-67-5

Ruxoprubart

Ruxoprubart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target complement factor B (CFB). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0879

CAS No.

2763342-87-4

Omoprubart

Omoprubart is a humanized monoclonal antibody of the IgG2-G4 κ subtype, specifically targeting the complement component 5 (C5). This antibody is designed for therapeutic interventions in diseases mediated by the complement system.

Cat. No.

AT0887

CAS No.

2894136-80-0

Greziprubart

Greziprubart is a human monoclonal antibody of the IgG1κ isotype designed to specifically target C5a. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0972

CAS No.

1917321-26-6

Crovalimab

Synonyms: SKY59; RO7112689

Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.

Cat. No.

AT0997

CAS No.

143653-53-6

Abciximab

Synonyms: C7E3

Abciximab (C7E3) is a chimeric monoclonal antibody fragment derived from both mouse and human sources, functioning as an inhibitor of glycoprotein (GP) IIb/IIIa. This agent effectively blocks platelet aggregation and leukocyte adhesion, mechanisms crucial for thrombosis and inflammatory responses, respectively. It achieves its therapeutic effects by targeting and binding to the GP IIb/IIIa receptor, as well as to vitronectin and Mac-1 receptors. This specificity makes Abciximab an essential tool in the study of platelet aggregation pathways and the development of anti-thrombotic therapies.

Cat. No.

AT1039

CAS No.

2162134-62-3

Garadacimab

Synonyms: CSL312

Garadacimab (CSL312) represents a pioneering advancement as a fully human IgG4 monoclonal antibody that specifically targets activated factor XII (FXIIa). This unique specificity renders it a valuable tool for investigating the pathophysiology and potential therapeutic interventions for hereditary angioedema.

Cat. No.

AT1045

CAS No.

3008610-20-3

Amrecibart

Amrecibart is a human IgG4 κ monoclonal antibody targeting coagulation factor XI. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Cat. No.

AT1058

CAS No.

2857858-76-3

Lofacimig

Lofacimig is a bispecific antibody designed as a VH-VH-G1(h-CH2-CH3) dimer, specifically targeting FXI and PTA. This configuration enhances its specificity and efficacy in engaging these particular antigens, making it a valuable tool for research into coagulation and anticoagulation pathways.

Cat. No.

AT1059

ANX005

ANX005 is a recombinant antibody specifically targeting C1q, the initiating molecule of the classical complement cascade. By inhibiting C1q, ANX005 is instrumental in the study of its role in autoimmune and neurodegenerative diseases. This antibody serves as a crucial tool for researchers investigating the mechanisms of immune response and disease progression in these conditions.

Cat. No.

AT1069

CAS No.

2098724-83-3

Abelacimab

Synonyms: MAA868

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody engineered to bind with high affinity to the catalytic structural domain of Factor XI (FXI). This interaction effectively locks FXI in its zymogen conformation, inhibiting its activation by Factor XIIa (FXIIa) or thrombin. Due to its specific mechanism of action, Abelacimab is an excellent tool for research into thromboembolic diseases, providing insights into the regulation of coagulation pathways and the development of antithrombotic therapies.

Cat. No.

AT1226

CAS No.

1985638-39-8

Marstacimab

Synonyms: PF-06741086

Marstacimab (PF-06741086) is a monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI). This antibody is utilized in the investigation of hemophilia, providing a valuable tool for exploring the regulation of coagulation pathways and potential therapeutic interventions.

Cat. No.

AT1242

Anti-Complement Factor B Antibody

Cat. No.

AT1249

CAS No.

2704554-77-6

Gruticibart

Gruticibart is a human IgG4 κ monoclonal antibody targeting Factor XI (F11). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is specifically designed for the study of coagulation processes and potential therapeutic interventions related to blood clotting disorders.

Cat. No.

AT1341

CAS No.

2096328-94-6

Pozelimab

Synonyms: REGN3918

Pozelimab (REGN3918) is a fully humanized IgG4 monoclonal antibody specifically developed to target and bind with high affinity to complement component 5 (C5) and its variants. This antibody effectively inhibits the cleavage of C5, thereby blocking complement-mediated hemolysis. It is an essential tool for investigating the pathophysiology of complement-mediated disorders and is suitable for use in various research settings focused on these diseases.

Cat. No.

AT1356

CAS No.

219685-93-5

Pexelizumab

Synonyms: h5G1. 1-SC

Pexelizumab (h5G1.1-SC) is a humanized single-chain variable fragment (scFv) monoclonal antibody that specifically targets the C5 component of the complement system. This antibody effectively inhibits key processes such as apoptosis and leukocyte infiltration, thereby modulating inflammatory responses. It is primarily utilized in research focused on cerebral ischemia-reperfusion (IR) injury and myocardial infarction, providing a valuable tool for investigating the role of the complement system in these conditions.

Cat. No.

AT1376

CAS No.

1531594-08-7

Tesidolumab

Synonyms: LFG316; Anti-Human C5 Recombinant Antibody

Tesidolumab (LFG316) is a fully human IgG1/λ monoclonal antibody with a molecular weight of 143 kDa in its non-glycosylated form. This antibody specifically targets and binds to complement component 5 (C5), effectively inhibiting its cleavage and the subsequent formation of the membrane attack complex (MAC). This blockade is crucial in preventing the cascade of events that lead to cell lysis and inflammation, making Tesidolumab a valuable tool for research into complement-mediated diseases and therapeutic interventions.

Cat. No.

AT1386

CAS No.

1426055-14-2

Lanadelumab

Synonyms: SHP643; DX-2930

Lanadelumab (SHP643) is a human IgG1 monoclonal antibody specifically targeting plasma kallikrein (pKal), exhibiting a potent inhibitory constant (Ki) of 0.12 nM. This antibody is capable of inhibiting both free and high molecular weight kininogen (HMWK)-bound forms of pKal. Lanadelumab is primarily utilized in research focused on hereditary angioedema, offering significant potential for elucidating the pathophysiology and therapeutic targeting of this condition.

Cat. No.

AT1394

CAS No.

2049079-64-1

Sutimlimab

Sutimlimab is a pioneering inhibitor of complement protein component 1, subcomponent s (C1s), representing the first in its class. This therapeutic targets C1s, a serine protease essential for the cleavage of complement components C4 and C2, which are critical in the formation of C3 convertase. Sutimlimab is primarily utilized in research focused on cold agglutinin disease, providing significant insights into the pathophysiological mechanisms and potential therapeutic interventions for this condition.

Cat. No.

AT1400

CAS No.

915810-67-2

Caplacizumab

Synonyms: ALX-0681; ALX-0081

Caplacizumab (ALX-0681) is a humanized nanobody targeting the von Willebrand factor (vWF), designed to disrupt the interaction between vWF and platelet glycoprotein Ibα. By inhibiting this binding, Caplacizumab effectively prevents vWF-mediated platelet adhesion, thereby reducing the formation of microthrombi. This agent is particularly useful for research focused on thrombotic thrombocytopenic purpura (TTP), offering a valuable tool for investigating the mechanisms and potential treatments of this condition.

Cat. No.

AT1512

Anti-RHD/CD240d Antibody